Kuppermann N
Department of Internal Medicine, University of California, Davis School of Medicine, USA.
Pediatr Clin North Am. 1999 Dec;46(6):1073-109. doi: 10.1016/s0031-3955(05)70176-0.
The evaluation of nontoxic-appearing, young, febrile children has been a subject of considerable debate. Of young, nontoxic-appearing children aged 3 to 36 months with temperatures of 39 degrees C or more and no clear source, approximately 2% to 3% have occult bacteremia. Of these bacteremias, approximately 90% are caused by S. pneumoniae, 5% by nontyphoidal Salmonella sp., and 1% by N. meningitidis. Most children with occult pneumococcal bacteremia improve spontaneously, but approximately 25% of untreated patients have persistent bacteremia or develop new focal infections, including 3% to 6% who develop meningitis. Occult meningococcal bacteremia, although rare, has frequent complications, including meningitis in approximately 40% and death in approximately 4%. Less is known about the natural history of untreated occult nontyphoidal Salmonella bacteremia. Empiric antibiotic treatment of children with occult bacteremia decreases the rate of complications, including meningitis. Few disagree that febrile, young children at risk for occult bacteremia require a careful clinical evaluation and close follow-up. The benefits of laboratory screening and selective empiric antibiotic treatment of febrile children at risk for occult bacteremia have to be weighed against the costs of screening tests and blood cultures, inconvenience, temporary discomfort to patients, risk for side effects of antibiotics, and the role of antibiotics in the development of bacterial resistance. Although great debate exists concerning the role of empiric antibiotics, a strategy for obtaining blood cultures and empirically administering antibiotics on the basis of an increased ANC, in addition to close clinical follow-up, may be effective in reducing the frequency and severity of uncommon but adverse sequelae. A highly effective S. pneumoniae bacterial conjugate vaccine will soon be available, which will benefit all children, and will alter the ways that clinicians evaluate fully immunized young, febrile children.
对看似无中毒症状的发热幼儿进行评估一直是一个备受争议的话题。在3至36个月、看似无中毒症状、体温达39摄氏度或更高且无明确病因的幼儿中,约2%至3%患有隐匿性菌血症。在这些菌血症中,约90%由肺炎链球菌引起,5%由非伤寒沙门氏菌属引起,1%由脑膜炎奈瑟菌引起。大多数隐匿性肺炎链球菌菌血症患儿可自行好转,但约25%的未经治疗患者会出现持续性菌血症或发生新的局灶性感染,其中3%至6%会发展为脑膜炎。隐匿性脑膜炎奈瑟菌菌血症虽然罕见,但并发症频发,约40%会发生脑膜炎,约4%会死亡。对于未经治疗的隐匿性非伤寒沙门氏菌菌血症的自然病程了解较少。对隐匿性菌血症患儿进行经验性抗生素治疗可降低包括脑膜炎在内的并发症发生率。很少有人会反对,有隐匿性菌血症风险的发热幼儿需要仔细的临床评估和密切随访。对于有隐匿性菌血症风险的发热儿童进行实验室筛查和选择性经验性抗生素治疗的益处,必须与筛查试验和血培养的成本、不便之处、给患者带来的暂时不适、抗生素副作用风险以及抗生素在细菌耐药性发展中的作用进行权衡。尽管对于经验性抗生素的作用存在很大争议,但除密切临床随访外,基于绝对中性粒细胞计数增加来获取血培养并经验性使用抗生素的策略,可能有效降低不常见但不良后遗症的发生率和严重程度。一种高效的肺炎链球菌结合疫苗即将问世,这将使所有儿童受益,并会改变临床医生评估已完全免疫的发热幼儿的方式。